NCT00697749CompletedPhase 3
Phase III Study to Compare Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Novel Adjuvanted Hepatitis B Vaccine Adminstered Intramuscularly, According to a 0, 6 Month Schedule, to Engerix™-B 20 mcg Administered According to a 0,1,6 Month Schedule in Healthy Volunteers Positive for the HLA-DQ2 Genotype
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- GlaxoSmithKline
- Enrollment
- 230
- Primary Endpoint
- Anti-HBs antibody concentrations
Study Overview
Brief Summary
This study compares the immunogenicity and safety of the novel adjuvanted HBV vaccine and Engerix™-B administered to subjects who were positively identified as having the HLA-DQ2 genotype
Detailed Description
At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 15 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •A male or female ≥ 15 years of age at the time of the first vaccination.
- •Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- •Written informed consent obtained from the subject/ from the parents or guardians of the subject.
- •Known to be seronegative for anti-HBs-antibodies, anti-HBc-antibodies and/or HBsAg.
- •Positive for the HLA-DQ2 genotype as determined in the previous sero-HBV-069 prevalence study.
- •If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination
Exclusion Criteria
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
- •Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
- •Previous vaccination against hepatitis B.
- •History of non-response to previous hepatitis B vaccination.
- •Known exposure to hepatitis B within 6 weeks.
- •History of hepatitis B infection.
- •Confirmed human immunodeficiency virus (HIV) infection.
- •A family history of congenital or hereditary immunodeficiency.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- •Acute disease at the time of enrollment.
- •Hepatomegaly, right upper quadrant abdominal pain or tenderness.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration/ administration during the study period.
- •Pregnant or lactating female
Arms & Interventions
Group A
Experimental
Intervention: HBV-MPL vaccine 208129 (Biological)
Group B
Active Comparator
Intervention: Engerix™-B (Biological)
Outcomes
Primary Outcomes
Anti-HBs antibody concentrations
Time Frame: At month 7
Secondary Outcomes
- Occurrence, intensity and relationship to vaccination of serious adverse events (SAEs)(During the study period)
- Occurrence, intensity and relationship to vaccination of unsolicited symptoms(During a 30 day follow-up period after each vaccination)
- Occurrence, intensity and relationship to vaccination of solicited local and general signs and symptoms(During a 4 day follow-up period after each vaccination)
- Cell mediated immunity(At Months 0 and 7)
- Anti-HBs antibody concentrations(Day 0, Month 1, Month 6 and Month 7)
Investigators
Similar Trials
Completed
Phase 3
Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in AdultsHepatitis BNCT00696891GlaxoSmithKline380
Completed
Phase 3
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 YearsHepatitis BNCT00383227GlaxoSmithKline165
Completed
Phase 3
Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® VaccineHepatitis BNCT00435812Dynavax Technologies Corporation2,428
Completed
Phase 3
Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).Hepatitis BNCT00697216GlaxoSmithKline340
Completed
Phase 3
Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15yHepatitis BNCT00698061GlaxoSmithKline145